How pharma economics hold back antibiotic development
07 March 2022
Dick Jenkins and other ‘angel’ investors have committed more than £20mn to the development of an experimental drug to tackle life-threatening infections. But they have come up against a substantial hurdle: a need for even more money.
Further reading: Financial Times
Author(s): Andrew Jack
Smart Innovations
OUR UNDERWRITERS
Unrestricted financial support by:
 |
Antimicrobial Resistance Fighter Coalition |
 |
Bangalore Bioinnovation Centre |
 |
INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS |
 |
BD |
AMR NEWS
Your Biweekly Source for Global AMR Insights!
Stay informed with the essential newsletter that brings together all the latest One Health news on antimicrobial resistance. Delivered straight to your inbox every two weeks, AMR NEWS provides a curated selection of international insights, key publications, and the latest updates in the fight against AMR.
Don’t miss out on staying ahead in the global AMR movement—subscribe now!